AlphaMeld Corporation
Sanatan Upmanyu is an accomplished professional in data science and life sciences, currently serving as the Head of Data Science at InveniAI GmbH, where leadership is focused on the development of the AlphaMeld Platform for drug discovery and healthcare innovation. With extensive experience as a Senior Director of Data Sciences in a Swiss site, Sanatan has driven growth and innovation across Europe. Proficient in statistical modeling, predictive analytics, and machine learning, Sanatan provides consulting services in pharmaceuticals and biotech, emphasizing real-world data applications. Past roles include Director of Data Sciences at BioXcel Corporation and Research Biologist at Ranbaxy, with a strong academic background in biotechnology and bioinformatics.
This person is not in any offices
AlphaMeld Corporation
Headquartered in Guilford, CT, AlphaMeld® Corporation (a wholly owned subsidiary of InveniAI LLC) stands as a global frontrunner in the application of AI, machine learning, and generative AI tools, catalyzing innovation throughout drug discovery and development. With a mission to identify and expedite transformative therapies for diseases with unmet medical needs, the company utilizes its cutting-edge AlphaMeld platform to extract valuable insights from petabytes of diverse data sets, propelling the creation of groundbreaking drug programs. The company's pioneering approach is underscored by successful collaborations with industry leaders and drug spinouts, solidifying its position as a trailblazer in the realm of AI-driven drug discovery. About The AlphaMeld® Platform The AlphaMeld platform employs a comprehensive approach to generate testable hypotheses, considering factors such as the ideal mode of pharmacotherapy, disease severity, gene ontology, disease pathways, proteinopathies, standard of care, emerging innovation, and enabling technologies. This is done while factoring in medical, scientific, strategic, and commercial considerations.